I think we have some time here. With the market generally imploding on deflation fears, and no news that'll move this coming soon, not sure you need to rush either. I don't think that 8K is near term. The due diligence to figure to out what's working and what isn't will take some time. Also, they need to see what they can out of lease wise. Finally, they need to see if and with whom they can partner the legacy drugs. Then, we're a synthetic biology oncology company, smaller, and hopefully wiser. Those deals and negotiations are critical at this point, and it's no fun to negotiate under duress, hence the initial 8-k move. The next one takes longer, but vital.